Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
13%(1 trials)

Phase Distribution

Ph phase_2
1
13%
Ph phase_3
1
13%
Ph not_applicable
1
13%
Ph phase_1
4
50%

Phase Distribution

4

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
4(57.1%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(8)

Detailed Status

Completed8

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (57.1%)
Phase 21 (14.3%)
Phase 31 (14.3%)
N/A1 (14.3%)

Trials by Status

completed8100%

Recent Activity

0 active trials
Showing 5 of 8
completed

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

NCT00667121
completedphase_1

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

NCT00939835
completedphase_1

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

NCT00940238
completedphase_2

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

NCT00086645
completedphase_3

Citalopram in Treating Postmenopausal Women With Hot Flashes

NCT00363909
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00667121

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

Completed
NCT00939835Phase 1

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

Completed
NCT00940238Phase 1

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

Completed
NCT00086645Phase 2

Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1)

Completed
NCT00363909Phase 3

Citalopram in Treating Postmenopausal Women With Hot Flashes

Completed
NCT00930293Not Applicable

Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety

Completed
NCT01149980Phase 1

Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

Completed
NCT01149967Phase 1

Bioequivalence Study of Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8